ROI-NJ
How N.J. company, Tris Pharma, is working to solve severe shortage of ADHD medication ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
A year-long shortage of ADHD medicine has created an endless loop of millions of parents searching desperately to find medication for their kids — often on a monthly basis. Monmouth Junction-based Tris Pharma is working to help.
Clinical Trials Arena
Pain points: Unsolved recruitment and trial design issues in pain clinical trials ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.
The Bio Report
Managing Pain without Addiction ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
Opioid overdose, abuse, and addiction affect an estimated 3 million Americans and accounts for $35 billion in U.S. healthcare costs every year. Tris Pharma is developing the opioid Cebranopadol, as an effective pain management therapy without the addictive potential of FDA-approved opioids.
Life Science Leader
To America, A New Biopharma Model ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses-platform technology licensing, generic medicines, and new drug development.
SLEEP REVIEW
How to Navigate the Narcolepsy Pharmacotherapy LandscapeManaging Pain without Addiction ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
With new narcolepsy drugs available, sleep specialists face the challenge of selecting the most suitable therapies for their patients.
NJBIZ Conversations: Ketan Mehta ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
Tris Pharma founder and CEO Ketan Mehta talks about his company’s work on a new, non-addictive pain treatment and other promising products in the pipeline.
PharmaVoice
Is America ready for a new kind of opioid? ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
Tris Pharma’s CEO is “betting the company” on a pain reliever with the power of an opioid and a lower chance of addiction.
BioBuzz
Flying Under the Radar, Tris Pharma Builds Strong Pipeline in ADHD, Pain, Neurological Disorders ![Tris Pharma External Link icon](/wp-content/uploads/2023/11/Tris_Pharma_External-Link_icon.svg)
In the continual wake of the opioid crisis gripping the nation, New Jersey-based Tris Pharma is developing a pipeline of pain treatments that are expected to be much safer than currently available products.